The role of PAX1 gene methylation in cervical cancer and precancerous lesions screening has been confirmed in previous studies. This study is to explore the feasibility of PAX1 gene methylation in predicting the efficacy of concurrent chemo-radiotherapy for cervical cancer. The research was conducted from August 2018 to December 2019, as 52 cervical cancer patients were enrolled in this study. Patients (FIGO stage IB to IVA) underwent concurrent chemo-radiotherapy received MRI and PAX1 methylation detection several times before the therapy, in the middle of treatment, immediately after Cartooned month and three months after treatment. During the research, quantitative methylation-specific PCR(QMSP) is used as the method of determining methylation levels of PAX1 gene and the specimen was taken from cervical scraping. According to the MRI result in the third month after the treatment,43 patients was classified as CR group, the other 9 as PR. Following this, dynamic changing trend of PAX1 during CCRT was analyzed and compared with clinical results. The methylation level of PAX1 gene was significantly reduced from the beginning to the end of treatment at the both CR group and PR group(P<0.05). The methylation level decreased significantly at the second test (middle time of treatment) in the CR group, but the PR group did not change significantly at the period. Furthermore, the methylation level of PAX1 gene was decreased obviously at the end of treatment in PR group. The molecule level change of PAX1 methylation level may predict the sensitivity and efficacy of concurrent chemo-radiotherapy treatment in cervical cancer.